Latest Research And Development Investment News

Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Parkway Corporate Limited delivered a record $5.21 million quarterly revenue and $0.73 million EBITDA in Q3 FY26, driven by ramp-up of a major water infrastructure project. Meanwhile, its flagship Queensland Brine Management Complex progresses through key development application milestones with public notification underway.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

CleanSpace Holdings Limited reported a 26% increase in revenue to $19.8 million for FY25, alongside a significant reduction in net loss to $478,276. The company’s strategic expansion and innovation efforts underpin its improving financial health and global market presence.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

TechnologyOne Limited has reported a robust first half for FY25, with annual recurring revenue exceeding $500 million well ahead of schedule and profit before tax climbing 33%. The company’s SaaS+ platform and strategic acquisition of CourseLoop are driving growth and positioning it for ambitious long-term targets.